Adaptimmune Therapeutics plc Stock price
Equities
ADAP
US00653A1079
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.57 USD | -0.63% | +17.16% | +97.98% |
Financials (USD)
Sales 2024 * | 81.85M | Sales 2025 * | 73.92M | Capitalization | 390M |
---|---|---|---|---|---|
Net income 2024 * | -96M | Net income 2025 * | -120M | EV / Sales 2024 * | 4.76 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 5.28 x |
P/E ratio 2024 * |
-13.2
x | P/E ratio 2025 * |
-6.87
x | Employees | 449 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 15.06% |
Latest transcript on Adaptimmune Therapeutics plc
1 day | -0.63% | ||
1 week | +17.16% | ||
1 month | -2.48% | ||
3 months | +127.50% | ||
6 months | +99.85% | ||
Current year | +97.98% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 57 | 07-12-31 | |
Adrian Rawcliffe
CEO | Chief Executive Officer | 52 | 15-02-28 |
Gavin Wood
DFI | Director of Finance/CFO | 54 | 20-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kristen Hege
BRD | Director/Board Member | 60 | Oct. 31 |
Andrew Allen
BRD | Director/Board Member | 57 | 23-05-31 |
David Mott
CHM | Chairman | 58 | 14-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - | |
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 1.58 | 0.00% | 1,068,461 |
24-03-27 | 1.58 | +3.95% | 1,184,494 |
24-03-26 | 1.52 | +5.56% | 1,194,956 |
24-03-25 | 1.44 | 0.00% | 1,175,504 |
24-03-22 | 1.44 | +7.46% | 1,671,980 |
Delayed Quote Nasdaq, March 28, 2024 at 03:59 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+97.98% | 390M | |
+2.73% | 108B | |
+9.59% | 103B | |
+6.58% | 23.48B | |
-12.59% | 21.93B | |
-3.29% | 19.68B | |
-35.36% | 18.37B | |
-13.29% | 16.33B | |
+4.68% | 13.72B | |
+34.25% | 12.15B |